Bandingkan Harga & Kinerja Lini Imaji Kreasi Ekosistem Tbk. (FUTR) vs Organon Pharma Indonesia Tbk. (SCPI)
Kinerja harga (24 Jam Terakhir)
Statistik utama
Statistik utama
Perbedaan Lini Imaji Kreasi Ekosistem Tbk. dan Organon Pharma Indonesia Tbk.: Lini Imaji Kreasi Ekosistem Tbk. diperdagangkan di Rp294 (kapitalisasi pasar 1,99 T, volume 24 jam 36,36 jt), sedangkan Organon Pharma Indonesia Tbk. diperdagangkan di Rp29.000 (kapitalisasi pasar 104,4 M). Perbedaan utamanya: Lini Imaji Kreasi Ekosistem Tbk. jauh lebih besar — sekitar 19,1× kapitalisasi pasar Organon Pharma Indonesia Tbk.. Mana yang lebih baik tergantung tujuan investasimu.
| FUTR | SCPI | |
|---|---|---|
Kapitalisasi Pasar | 1,99 T | 104,4 M |
Volume | 36,36 jt | — |
Lot | 363,6 rb | — |
Perputaran | 10,52 M | — |
Harga Rata-rata | 289,44 | — |
Nilai Transaksi | 10,52 M | — |
Harga Ekuilibrium Indikatif | 294 | — |
Volume Ekuilibrium Indikatif | 6,93 rb | — |
Perbandingan imbal hasil
Imbal hasil berjalan pada periode standar
Perbandingan imbal hasil
Imbal hasil berjalan pada periode standar
Berita terkini
Berita terbaru kedua aset
Berita terkini
Berita terbaru kedua aset
Tentang Lini Imaji Kreasi Ekosistem Tbk.
PT Lini Imaji Kreasi Ekosistem Tbk (the “Company”) was established under the name of PT LinikiniAspirasi Kreasi based on Notarial Deed No. 74 of Janty Lega, S.H., M.Kn., dated July 29, 2021. The Company started its commercial operations in 2021. The immediate and ultimate parent entities of the Company are PT Digital Futurama Global and PT Investasi Gemilang Maju, respectively.
Selengkapnya di halaman FUTR →Tentang Organon Pharma Indonesia Tbk.
PT Merck Sharp Dohme Pharma Tbk was established within the frame work of the Foreign Capital Investment Law No. 1 year 1967 as amended by Law No. 11 year 1970 based on Notarial Deed No. 17 dated 7 March 1972 of Djojo Muljadi, S.H. The company originally incorporated as PT. Essex Indonesia, as a joint venture between Schering Corporation, a worldwide, research-based pharmaceutical enterprise headquartered in the United States, and an Indonesian businessman.
Selengkapnya di halaman SCPI →
